Business
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin’s CEO Mark White, who will provide an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will detail the Compa
About this update from Nexalin Technology, Inc.
[{"type":"image","alt":"Nexalin Technology, Inc.","displaySize":"","headline":null,"caption":"Nexalin Technology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kPm7LNc3A4iAJ.KL_fneQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76","width":200,"height":200}},"lazy":false},{"type":"text","content":"HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET.","length":196,"tagName":"p"},{"type":"text","content":"The exclusive event, hosted by RedChip Companies, will feature Nexalin’s CEO Mark White, who will provide an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will detail the Company’s growing body of clinical evidence, including collaborations with leading institutions like UC San Diego, and share updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model—designed for scalable, at-home treatment. With regulatory approvals secured internationally and U.S. expansion underway, Nexalin is positioned at the forefront of a $537 billion mental health market. Investors will also hear how Nexalin’s patented technology, real-time AI-driven patient monitoring, and expanding global footprint create a compelling opportunity in the high-growth neurostimulation space. A live Q&A session with White will follow the presentation.","length":960,"tagName":"p"},{"type":"text","content":"To register for the free webinar, please visit: https://www.redchip.com/webinar/NXL/88925127595.","length":96,"tagName":"p"},{"type":"text","content":"Questions can be pre-submitted to [email protected] or online during the live event.","length":82,"tagName":"p"},{"type":"text","content":"About Nexalin Technology, Inc.","length":30,"tagName":"p"},{"type":"text","content":"Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are non-invasive and undet...